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Abstract
Background: Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the development of hereditary diffuse gastric cancer (HDGC) syndrome. The risk assessment and management of HDGC families that do not carry a CDH1 variant is limited. It is therefore difficult for such families to make informed choices about surveillance and risk reducing surgery. This study aimed to identify new candidate genes for HDGC predisposition in families with no detected pathogenic CDH1 variants (CDH1-NPV). 
Methods: Whole exome sequencing (WES) was performed on DNA extracted from blood obtained as part of the Familial Gastric Cancer Study. Analysis was performed across 39 individuals (28 affected and 11 unaffected) from 22 CDH1-NPV families that fulfil the international criteria for HDGC. Genes with loss-of-function variants were prioritised using gene interaction analysis to identify clusters of genes that could be involved in HDGC predisposition.
Findings: Protein-affecting germline variants were identified in known cancer predisposition genes or lesser studied DNA repair genes in six HDGC families. A frameshift deletion within PALB2 was found in a family with a history of gastric and breast cancer. Two MSH2 variants were identified, one frameshift insertion and one previously described start loss, in unrelated affected individuals. One family was identified with a unique combination of variants in DNA repair genes ATR and NBN. A missense variant and a splice acceptor variant were seen in two unrelated families in DNA repair gene RECQL5.
Interpretation: This study supports the role of known cancer predisposition gene PALB2 in the HDGC syndrome. It also puts forward new candidates in relation to HDGC risk within CDH1-NPV families.




CDH1-NPV	No pathogenic variant in CDH1
CNV	Copy number variant
ExAC	Exome Aggregation Consortium 
GC	Gastric cancer
GO	Gene ontology
HDGC	Hereditary diffuse gastric cancer
MSI	Microsatellite instability
SR	Signet ring cells







Evidence before this study
The understanding of hereditary diffuse gastric cancer (HDGC) predisposition in families with no pathogenic variants in CDH1 (CDH1-NPV) is limited by the rarity of the disease, making large scale association studies difficult to perform. In 2015, variants in DNA repair-related genes were described in CDH1-NPV HDGC families by Hansford et al. These genes included the known breast cancer risk genes PALB2, BRCA2, and ATM. The further study of these genes, other known cancer predisposition genes, and DNA repair associated genes will aid in the disease management for HDGC families whose risk is currently unknown. 
Added value of this study
This study is one of the largest germline whole exome sequencing studies of CDH1-NPV HDGC families to date. Both affected and unaffected individuals were recruited from strong HDGC families, providing the opportunity to look for protein affecting variants that segregate with the phenotype. A unique approach to pathway analysis was taken that creates sets of physically interacting genes that are enriched for variants in HDGC families and provides those sets with a gene ontology term. This may allow future studies to identify other functionally linked candidate genes with variants in HDGC families that may also by implicated in HDGC predisposition. By combining findings from this study with data from previously published CDH1-NPV HDGC studies, we were able to create a more complete analysis of the role of cancer predisposition genes PALB2 and BRCA2. Both analysis approaches aim to aid in the identification of other DNA repair related HDGC risk genes and provide more information about HDGC risk outside of the realms of CDH1.
Implications of all the available evidence
We identified a cluster of interacting DNA repair related genes that could be involved in the predisposition of HDGC. The identification of a pathway involved in HDGC predisposition will allow future studies to better understand the clinical implications of genes that have not previously been reported but may be functionally linked to this malignancy. The evidence was ascertained by combining occurrences of PALB2 and BRCA2 in several germline HDGC predisposition studies. Taken together, this indicates that PALB2 variants may well have a greater role in HDGC than previously suspected. This could provide CDH1-NPV HDGC families with greater information about their risk of HDGC and subsequently provide more informed choices for risk reduction and disease management. 

Introduction
Gastric cancer is the fourth most common cancer globally. The best characterised inherited gastric cancer is the diffuse type (DGC), the hallmark of which is the presence of multiple foci of signet-ring cells.1 The term hereditary diffuse gastric cancer (HDGC) is applied to families with a history of diffuse gastric cancer that meet the following criteria:2,3
a) At least two cases of GC in first or second-degree relatives regardless of age of onset, with one confirmed case of DGC. 
b) One case of DGC diagnosed before the age of 40. 
c) Any family history of DGC and lobular BC diagnosed before the age of 50. 
Germline mutations in the E-cadherin gene (CDH1) explain 25-30% of hereditary diffuse gastric cancer cases, with over 100 pathogenic germline variants currently described within this gene.4 For HDGC families with known pathogenic CDH1 mutations, there are guidelines for risk assessment, disease management and surveillance including regular endoscopies, and risk reducing therapies including a prophylactic gastrectomy.5,6 However, for families with no pathogenic variant (NPV) in CDH1, the risk assessment is uncertain and therefore the efficacy of risk reducing strategies is harder to assess. 
Other familial cancer syndromes that have been linked to gastric cancer predisposition include Lynch syndrome, which is categorised by mutations in DNA mismatch repair genes, Peutz-Jeghers syndrome caused by mutations in STK11, and Li-Fraumeni syndrome which is associated with germline TP53 mutations.2,7–9 DGC does not appear to be overrepresented in these syndromes, although this has not been comprehensively studied.
Additionally, predicted pathogenic variants in the DNA double strand break repair genes ATM, BRCA2, and PALB2 have been identified in a few HDGC families.4,10 However, given the rarity of the findings, the associated DGC risk is hard to quantify, and therefore these variants are not used in routine clinical testing to aid management of HDGC families.
Here we present data from one of the largest germline HDGC whole exome sequencing studies to date, consisting of 22 CDH1-NPV HDGC families, including individuals affected with DGC and unaffected family members where available. 
Materials and Methods:
Study Population:
Twenty-eight individuals diagnosed with DGC and eleven unaffected relatives were recruited from 22 DGC families (table 1) that had tested negative for CDH1 pathogenic germline mutations as part of an ethically approved study (MREC 97/5/32). Families (including first and second degree relatives) were categorised as having DGC syndrome based on the current criteria.2,3,6 As part of routine clinical testing, immunohistochemistry staining for mismatch repair proteins was performed on tumours.
Whole exome sequencing and variant filtering:
DNA was extracted from blood or saliva and prepared for PE125 whole exome sequencing using the Nextera Rapid Capture Exome enrichment kit (Illumina). Sequencing was performed on HiSeq-4000 or HiSeq-2500 machines. VCF files were generated using a standard pipeline following GATK best practice recommendations for whole exome data (see supplementary material p1). The dataset was filtered to select 3973 uncommon (AF <0·05 in European 1000 genomes), protein affecting variants: loss of function (stop gained, stop lost, start lost, splice acceptor variant, splice donor variant, or frameshift variant), predicted deleterious and damaging missense variants (as flagged by SIFT and PolyPhen respectively) and inframe indels , which were observed in at least one of the 28 affected HDGC samples (HDGC affected allele count > 0).  The 11 unaffected family members were treated separately on a per family basis as a control group on which to perform segregation analysis for identified candidate variants. The described filters were introduced with the aim of removing variants that were least likely to be affecting HDGC predisposition. All candidate variants were manually examined for allele frequency (AF) in healthy controls, allele count (AC) in affected and unaffected individuals within families and protein affect further downstream.
Variants were aggregated into 2847 genes which were filtered to select those that contain at least one loss of function variant. The top 1% most variable genes were also removed; this was determined by the number of rare, protein affecting variants per gene. A set of 732 genes (1228 variants) were retained for further analysis. Variant and gene filtering steps are summarised in figure 1.
Gene interaction network analysis:
Gene interaction network analysis was used to identify variant-enriched candidate genes with interacting protein products; non-antagonistic, physically interacting proteins may have a similar effect on cell function and therefore may produce a shared phenotype when mutated. The 732 filtered genes were put through the Cytoscape GeneMania plugin, placing physically interacting genes into clusters.11 A cluster was defined as a set of five or more physically interacting genes.
The Gene Ontology Consortium enrichment analysis web tool was used to assign GO terms to clusters using the PANTHER Overrepresentation Test (version 13.0) applying the default Bonferroni correction for multiple testing.12 Of the significant terms highlighted by the analysis, the most significant term that encompasses between ten and 200 genes was selected, in compliance with previous studies.13
Allelic counts of all 1228 filtered, loss of function variants within the selected GO terms (regardless of GeneMania clustering) were aggregated and contingency tables were drawn. Variants were also aggregated for each GO term over a comparably filtered set of 503 Europeans from phase-3 of the 1000 genomes study (see supplementary material p1).14 A one-tailed Fisher’s exact test was performed using the R Stats package to test for an enrichment of loss of function variants within each selected GO term in HDGC in comparison to the European 1000 genomes set. For this test, only one occurrence of a variant was counted per family in the HDGC set. A link to the custom R scripts used for this analysis can be found within the supplementary material (supplementary material p1). 
Validation by Sanger sequencing:
Candidate variants were validated by Sanger sequencing. Germline DNA from blood and extracted tumour DNA was quantified using the Qubit dsDNA HS kit (Invitrogen) and custom flanking primers were designed for each variant (primer sequences are given in supplementary data p2). DNA fragments were amplified by PCR and the products were sequenced on an ABI Genetic Analyser (Applied Biosystems) using BDT V3.1 (Invitrogen) according to the manufacturer’s instructions for Sanger sequencing.
Tumour immunohistochemistry and microsatellite instability analysis
The Ventana Benchmark mismatch repair (MMR) panel (MLH-1 (M1), PMS2 (EPR3947), MSH2 (G219-1129) and CONFIRM anti-MSH6) was used to perform immunohistochemistry analysis for known mismatch repair genes within selected tumours.
To perform microsatellite instability analysis (MSI), 5µm FFPE sections were mounted on glass slides for dewaxing and manual microdissection. DNA was extracted with the QIAamp DNA FFPE Tissue kit. Five standard microsatellite markers were used to evaluate the DNA (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using the Promega MSI Analysis System (v1.2). Poorly and moderately differentiated gastric tissue were compared to adjacent tumour-free tissue.
Analysis of PALB2 and BRCA2 variants in published studies
Publications reporting the sequencing results of CDH1-NPV HDGC probands, were searched for loss of function PALB2 and BRCA2 variants. Only publications released after the initial report of PALB2 and BRCA2 in HDGC by Hansford et al were used.4 For each of the four identified publications and this current study, allele counts of loss of function PALB2 variants were aggregated. The same counts were performed across the 503 European 1000 genomes samples and 27,173 non-TCGA,  non-Finnish Europeans from the Exome Aggregation Consortium (ExAC) control datasets.15 Within all tested sets, the well-characterised non-pathogenic BRCA2 polymorphic stop codon in c.9976A>T was removed. A one-tailed Fisher’s exact test was performed using the R Stats package to test for an enrichment of loss of function PALB2 or BRCA2 variants in HDGC in comparison to either control set.
Role of the funding source
Funders had no role in study design, data collection, analysis and interpretation, or the writing of the report. EF, JR and MT had access to the raw data. The corresponding author had full access to all of the data and the final responsibility to submit for publication.
Results
Gene interaction network analysis:
A whole exome sequencing dataset of 39 individuals from 22 CDH1-NPV HDGC families (table 1) was filtered to select 3973 uncommon, protein-affecting variants that were aggregated into 2847 genes. Genes were further filtered to exclude highly-variable genes (top 1%) and to retain the ones, which had at least one loss of function variant in the affected subjects, creating a set of 732 genes (1228 variants). Eight highly-variable genes were excluded, including mucin, human leukocyte antigen, and olfactory receptor genes. These genes are known to contain a large number of rare variants in a healthy population and so were excluded on the basis that such genes were unlikely to play a role in HDGC predisposition. In addition, the presence of affected and unaffected family members within our set allowed for the downstream selection of variants that segregate with phenotype on a per family basis.
The set of 732 filtered genes was input into gene interaction network analysis, which identified two physical interaction clusters, shown in figure 2, to which Gene Ontology (GO) terms were applied. A cluster of eight genes shown in figure 2a) was associated with the ‘double strand break repair’ (GO:0006302) GO term (PANTHER Overrepresentation Test P value = 0·000000355). A second cluster of ten genes (figure 2b) was associated with the GO term ‘negative regulation of extrinsic apoptotic signaling pathway via death domain receptors’ (GO:1902042)(PANTHER Overrepresentation Test P value = 0·00517).
Loss of function variants within the filtered set of 1228 variants were aggregated under the two significant gene ontology terms, including the GO-term related genes that were not initially clustered by GeneMania. A one-tailed Fishers exact test was applied to the aggregated allelic counts for each GO term in the HDGC set  versus a comparably filtered European 1000 genomes set to look for an enrichment (allelic counts can be seen in supplementary data p2). The ‘double strand break repair’ term was confirmed to be significantly enriched in HDGC (P=0·000512). In comparison, the ‘apoptotic signaling pathway’ term was not enriched in HDGC (P=0·186)suggesting that the differences in allele counts seen in double strand break repair cannot entirely be explained by the technical differences that arise when using an externally produced control dataset.
The significantly enriched double strand break repair set was further explored in detail. BRCA2 was a part of this set but it was disregarded from further study as it contained the well-characterised, benign polymorphic stop codon c.9976A>T.16 Other genes in this set included PALB2, MSH2, RECQL5, ATR, and NBN, all of which were shown to be physically interacting in GeneMania (Figure 2a). Candidate variants are summarised in table 2.
Candidate variants in HDGC families:
A heterozygous 2bp frameshift deletion was identified in PALB2 (c.757-758TAG>T). This loss of function variant at amino acid position 253 is predicted to result in an early stop codon seven amino acids downstream. Family 4 (figure 3), in which this PALB2 variant was found, has a history of breast, lung, and laryngeal cancer as well as DGC. Exome sequencing was performed on three siblings from this family; a proband with DGC at the age of 55 years, and two unaffected siblings. The variant was identified in the affected proband and in one of the siblings. The affected proband had previously received treatment for a Helicobactor pylori (H. pylori) infection but had tested negative at subsequent endoscopies.
The mismatch repair gene MSH2 is a member of the Lynch Syndrome associated gene set. Within this gene, two loss of function variants were identified; a start loss (c.1A>C) in family 12 (supplementary material p4) and a frameshift insertion of 4bp (c.967-968T>TCTCA) in family 8 (supplementary material p5). Both variants were seen in families with a strong history of DGC, however only DNA from the probands was available for sequencing and segregation analysis could not be performed. Heterozygosity of both variants was maintained within tumour DNA, as confirmed by Sanger sequencing. Clinical immunohistochemistry (IHC) staining for mismatch repair proteins was performed on tumours from both samples, with both tumours showing normal expression levels of the MSH2 protein and the other MMR proteins when compared to adjacent tumour-free tissue (supplementary material p6). Representative tumour samples from both individuals did not show evidence of MSI (supplementary material p6) and both individuals had previously tested negative for H. pylori.
Variants in DNA repair genes ATR and NBN were seen within family 11 (figure 4). The proband of this family was diagnosed with DGC at age 28, two siblings underwent risk-reducing gastrectomies and were found to be signet ring cell positive. For the purpose of this analysis, these individuals are treated as affected family members. The family had an unusual history, with both parents being likely affected with DGC; the father was diagnosed with DGC and the mother had metastatic disease characterised by signet rings which were from likely gastric primary. All individuals sequenced within this family tested negative for H. pylori. The proband and both siblings were double heterozygotes for loss of function variants in ATR and NBN. A splice donor variant (c.1124+1G>C) in NBN was seen in the three siblings but not the father and so was presumed to have been inherited maternally (DNA was only available for the father). A predicted stop gain variant (c.6075A>T) in ATR was seen in all three siblings and the father. Therefore, the three siblings carried the loss of function variants in both NBN and ATR. An unaffected second-degree relative within family 11 did not carry either variant. There were no other strong candidates within this family and a clinical Affymetrix CytoScan 750K SNP genotyping array revealed no clinically relevant copy number variants in the father.
Two variants were identified in the helicase gene RECQL5 in different families; one missense variant (c.2828C>T) in family 21 (supplementary material p7) and one loss of function splice acceptor variant (c.2806-2T>C) in family 6 (supplementary material p8). In both families, gastric cancer and breast cancer can be seen across three generations. The proband of family 6 tested negative for H. pylori and  the H. pylori status of the proband from family 21 is unknown. Within family 21 sequencing was performed on both an affected and unaffected individual, with the missense variant only appearing in the affected individual. 
Other genes within the double strand break repair cluster were not explored further as the genotype of individual variants did not segregate with the phenotype in families containing affected and unaffected members.
Loss of function variants in PALB2 and BRCA2 in published HDGC studies:
The enrichment of loss-of-function PALB2 and BRCA2 variants in HDGC was assessed using previously published studies.2,4,10 In total, five HDGC probands were identified with loss of function PALB2 variants, out of 312 tested families across the four studies (table 3). In these studies, PALB2 mutation carriers account for 1·5% of HDGC families; in comparison to 0·0037% of non-TCGA, non-Finnish European ExAC samples (Fisher’s Exact Test, P = 1·43x10-9) and 0·2% of European 1000 genomes samples (P = 0·039). In contrast, there was no enrichment of BRCA2 loss of function variants in HDGC probands in comparison to ExAC (P = 0·47) and 1000 genomes (P = 1).
Discussion
Predicted pathogenic (protein affecting) germline variants in known cancer predisposing DNA repair genes (including PALB2, MSH2, ATR, NBN, and RECQL5) were found in greater than 25% of HDGC CDH1-NPV families analysed in this study and these findings reflect the on-going expansion of cancer phenotypes in existing predisposition genes as genomic analyses extend to rarer cancer subtypes. Genes that were once seen as causing predisposition in one or two specific cancer types are now being further identified in the context of other cancers. This is largely the case for DNA damage repair genes, although specific repair pathways are closely associated to a few predominant cancer types. For example, mismatch repair genes were initially associated with colorectal cancer, but then subsequently associated with a risk of developing gastric and pancreatic cancer, amongst others.17,18 However, simply identifying predicted pathogenic variants in known cancer predisposing genes does not imply causality. This is particular the case in MSH2 where pathogenic germline variants identified in our study were not accompanied by the MMR-deficient tumour phenotype. For this, larger studies with matched controls are required, which is not feasible for rare diseases. The generation of large exome/genome control datasets, such as ExAC and 1000 genomes, can be used to strengthen possible associations as we have illustrated in the case of PALB2. When combining our data with those from previously published relevant studies, including those where no PALB2 variants were found, we saw a significant overrepresentation of PALB2 (but not BRCA2) pathogenic variants compared to ExAC and 1000 genomes controls. The discrepancies in P values seen in both controls is likely due to differences in sample size. Both control sets contain a loss of function PALB2 variant, however with 503 Europeans from phase-3 1000 genomes, this is much less significant than when using the 27,173 non-TCGA ExAC samples.14 In addition to these published families, another HDGC family with a strong family history of diffuse gastric cancer with a PALB2 stop gain variant (c.1438A>T) was reported to us by collaborators during the time course of this study. In a number of the cases described by Sahasrabudhe et al, tumour molecular profiling was also performed, showing that PALB2 mutation carriers had mutational signatures indicative of homologous recombination defects.10 The PALB2 protein plays a critical role in homologous recombination during double strand break DNA repair by recruiting BRCA2 and RAD51 to DNA breaks. Mutations in this gene are associated with an increased risk of breast and pancreatic cancer.19–21 Even within PALB2 families, cases of DGC are likely to be rare and could be masked by a larger number of sporadic gastric adenocarcinomas, which means that associations with cancer subtypes may be missed in epidemiological studies of PALB2 families unless the pathology on all reported cancers is known. An analogous development has recently occurred with BRCA1 where a rare serous subtype of endometrial cancer has shown to be overrepresented in BRCA1 variant carriers, an example of a novel cancer association in a gene has been intensively studied for over 20 years.22
Similarly, ATR and NBN are also involved in initiating the response to double strand DNA breaks. The DNA repair signalling gene NBN produces one of three proteins that form the MRN complex, alongside MRE11 and RAD50. The MRN complex is involved in the activation of the ataxia proteins ATM and ATR, both of which play roles in the further recruitment of damage repair proteins, cell cycle regulation and apoptosis. Loss of function variants are seen in NBN and ATR independently of each other in the parents of family 11, both of which had DGC or suspected DGC. The variants are co-inherited in all three siblings within the family. Independently, these variants may be conferring a risk to DGC, although an extensive maternal and paternal family history show no other incidences of gastric cancer and only one instance of late-onset prostate cancer. Slavin et al also identified a stop gain variant in ATR in an individual with intestinal type adenocarcinoma and a strong family history of gastric cancer.23
The unusual cancer pattern seen in family 11 could be attributed to multi-locus inherited neoplasia alleles syndrome (MINAS), in which pathogenic mutations are inherited in multiple cancer predisposing genes, leading to a distinct or severe phenotype.24 The close relationship between NBN and ATR in double strand break repair could indicate a potential combinatorial effect of these variants. An indication of this could be the young age of onset of DGC or signet ring cells seen in the three siblings. However, the combinatorial effect of double heterozygosity of mutations in DNA repair genes has been studied extensively in BRCA1 and BRCA2 with breast cancer, and this appears to be no more deleterious than a single mutation.25 Nevertheless, such double heterozygosity may have implications for genetic counselling that should be considered. 
Genetic variants in the mismatch DNA repair pathway are associated with Lynch Syndrome. There were two variants identified in MSH2, a frameshift insertion and a start loss variant. A similar MSH2 initiation codon variant (c.1A>G) has been previously described as having a mild effect on protein function and so should not be treated as a loss of function variant.26 The function of MSH2, measured by the presence of microsatellite instability, has been shown to be reduced in cases and tumours with this  start loss variant.26 However both cases shown here have normal expression of MSH2 after IHC staining and no microsatellite instability within the tumours. While it is most likely that these cases represent phenocopies, with neither tumour appearing to be caused by a mismatch repair deficiency, a novel (non-MMR mediated) mechanism of MSH2-related carcinogenesis in DGC cannot be ruled out.
The helicase RECQL5 is important for preventing aberrant homologous recombination and preventing the accumulation of double strand DNA breaks and preserving genome stability.27 Two individuals were sequenced within family 21, with the missense RECQL5 variant segregating between the affected proband and the unaffected father. The splice acceptor variant in family 6 was seen in an individual diagnosed with DGC at age 37. Both families have a history of breast and gastric cancer.
Previous studies have explored the role of known cancer predisposition genes in CDH1-NPV HDGC. Sahasrabudhe et al reported  PALB2, BRCA1, and RAD51C germline variants in DGC families.10 Hansford et al described variants in ATM, BRCA2, MSR1, and STK11, a frameshift deletion in PALB2, as well as uncovering a role for CDH1 related adhesion gene CTNNA1.4 Although our study found no variants of interest in ATM, BRCA1, BRCA2, CTNNA1, MSR1, RAD51C, or STK11, an exploration of PALB2 variants in all HDGC families sequenced within recent literature showed an enrichment of loss of function variants in comparison to control sets. The results of these studies make a case for including PALB2 in genetic testing for CDH1-NPV HDGC families and it is possible that PALB2 mutation carriers with DGC may benefit from platinum-based chemotherapy and treatment with PARP inhibitors. On the other hand, the evidence is not yet strong enough to recommend DGC surveillance in PALB2 mutation carriers, as the absolute level of risk is likely to be low in the absence of a family history.
Sporadic stomach cancers have been analysed as part of the Cancer Genome Atlas (TCGA) study28 This study identified an association between truncating PALB2 mutations and sporadic stomach adenocarcinoma.28 Of these, we selected 88 DGC individuals, as described by Bass et al, and did not identify any truncating PALB2 variants. 29 However, the average age at diagnosis of the whole stomach adenocarcinoma cohort was 66 years so this is perhaps not unexpected. 
The rarity of CDH1-NPV HDGC makes the collection of large datasets challenging. This study employed gene interaction network analysis to prioritise candidate variants that co-segregated with phenotype and are likely to be involved in HDGC predisposition based on prior biological knowledge. This does not overcome the problem of low statistical power due to the small sample size that is often seen with rare cancer datasets.  However, this method allows for the selection of the most plausible candidates from the available data. 
An additional analysis of copy number variants (CNVs) within this dataset was attempted using the XHMM algorithm.30 Although it has not suggested any plausible candidates, the CNV analysis on germline WES data is currently not validated and therefore some causal CNVs could have been missed within this study.
In summary, DNA damage repair genes were found to be enriched for rare protein affecting variants within HDGC families with no detected pathogenic CDH1 variants (CDH1-NPV). Further studies of these genes in similar families are required to gather more evidence, in order to increase our knowledge about the genetic basis of HDGC to make better informed decisions about risk reduction and possibly influence management in affected family members. Lastly, many CDH1-NPV families remain unexplained even after WES, and while WGS may identify some further candidates in regulatory elements or structural variants it seems unlikely that a second high-impact gene implicated in HDGC will be discovered beyond CDH1. With this in mind, focusing on moderate or low impact cancer genes such as PALB2 may be the way forward for studies into CDH1-NPV HDGC predisposition.
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Family	Family ID	Number of samples sequenced	Diagnosis of proband (age)	Other cancers diagnosed in first or second degree relatives (age)	Candidate gene
		Affected	Unaffected			
1	GPQ_045	2	0	DGC (41)*	DGC (44)*, GC (57)	
2	GPQ_047	2	4	DGC (27)*	PnC, OvC (22), DGC (24)*, DGC (28)	
3	GPQ_048	1	0	DGC (40)*	GC (28), DGC (48)	
4	GST_172	1	2	DGC (55)*	BC, LC, LxC, DGC (44), DGC (52)	PALB2
5	GST_230	1	0	DGC (36) and CRC (47)*	DGC (37), LC (54), CRC (57), BC (50), DGC (61), DGC (79), LC (83) 	
6	GST_256	1	0	DGC (37)*	BC, GC (63), GC (64)	RECQL5
7	GST_257	2	0	DGC (36)*	CRC, BC (43) and DGC (55)*	
8	GST_275	1	0	DGC (47) and LBC (36)*	GC (44)	MSH2 **
9	GST_296	1	0	DGC (44)*	DGC (28)	
10	GST_345	1	2	DGC (28)*	BC, GC (44), GC (47)	
11	GST_349	4	1	DGC (23)*	SR*, SR*, BC (40s), DGC (45)*, PC (60s), CRC (75)	ATR, NBN
12	GST_358	1	0	DGC (68)*	LC, GC (49), GC (50), GC (76)	MSH2 **
13	GST_368	1	0	DGC (47)*	GC, GC (50s), GC (60s)	
14	GST_440	1	0	DGC (23)*	DGC (40s), DGC (46), ThyC (30)	
15	GST_441	1	0	DGC (53)*	GC (49), GC (67), GC (71)	
16	GST_444	1	0	DGC (37)*	GC, BC (54), BC (65), CRC (66), 	
17	GST_446	1	0	DGC (45)*	DGC (42)	
18	GST_455	1	0	DGC (48)*	GC (44), GC (54)	
19	GST_459	1	1	DGC (35)*	LC, UtC (65)	
20	GST_460	1	0	DGC (55)*	GC (51), CRC (76)	
21	GST_463	1	1	DGC (28)*	GC (53), BC (76), GC (80) 	RECQL5
22	GST_464	1	0	DGC (30)*	GC, DGC (67)	
Table 1: Characteristics of the 28 affected individuals from 22 families sequenced within this study. First or second degree relatives of each proband that were diagnosed with cancer are described and those that were sequenced within this study are marked with *. In total, 39 individuals were sequenced, including 11 unaffected relatives.
** No microsatellite instability was detected in tumour.  Cancers described include: breast cancer (BC), colorectal cancer (CRC) , diffuse gastric cancer (DGC), gastric cancer (GC),  laryngeal cancer (LxC), lung cancer (LC), ovarian cancer (OvC), peritoneal cancer (PnC) , prostate cancer (PC), signet ring cells (SR) , thyroid cancer (ThyC), uterine cancer (UtC) 


Table 2: Candidate variants identified via gene interaction analysis on WES data of HDGC families.

Family	Number of sequenced individuals	Diagnosis of proband (age)	Other cancers diagnosed in first or second degree relatives	Gene	Variant	Consequence	Protein Change	MAF 1000 genomes European	MAF ExAC non-TCGA European	SIFT	PolyPhen
4	3	DGC (55)	Breast, Lung, Larynx	PALB2	c.757-758TAG>T	Frameshift deletion	p.Leu253fs	0	0	NA	NA










Table 3: PALB2 variants identified by in HDGC sequencing studies
Study	Race/Ethnicity	ID	Diagnosis of proband	Tumour work completed?	Variant	Consequence	Protein Change	MAF 1000 genomes European	MAF ExAC non-TCGA European
Hansford 20154	European	P124	DGC (45)	No	c.1193AC>A	Frameshift deletion	p.Val398fs	0	0
Sahasrabudhe 201710	European	CG-12	IGC (69)	Yes	c.1240C>T	Stop gain	p.Arg414Ter	0	0
Sahasrabudhe 201710	European	CG-008	DGC (48)	No	c.1240C>T	Stop gain	p.Arg414Ter	0	0
Sahasrabudhe 201710	European	GM037589	NA (46)	No	c.1240C>T	Stop gain	p.Arg414Ter	0	0
Sahasrabudhe 201710	European	CG-05	DGC (50)	No	c.3201+1G>T	Splice site variant		0	0
Sahasrabudhe 201710	European	CG-039	DGC (47)	No	c.1882_1890delAAGTCCTGC	Inframe deletion	p.Lys628_Cys630del	0	0
Sahasrabudhe 201710	Latin_american	CG-028	IGC (81)	Yes	c.1882_1890delAAGTCCTGC	Inframe deletion	p.Lys628_Cys630del	0	0
Sahasrabudhe 201710	Latin_american	3CG-103	Mixed (79)	Yes	c.2753C>A	Missense	p.Pro918Gln	0	0
Fewings (this study)	European	GST_172_301	DGC (55)	No	c.757_758TAG>T	Frameshift deletion	p.Leu253fs	0	0
Teixeira (unpublished)	European	GM048157	DGC (56)	No	c.1438A>T	Stop gain	p.Lys480Ter	0	0






Figure 1: Variants filtering and analysis 





Figure 2: Gene clusters identified via gene interaction analysis






Figure 3: a) The pedigree for family 4. b) Chromatograms showing the frameshift variant in sample 1 and sample 2 against control DNA. Whole exome sequencing was performed on the circled samples, where shading indicates an affected and white indicates an unaffected individual.
 Figure 4: a) The pedigree for family 11 showing the segregation of variants in NBN and ATR amongst the four affected family members for which DNA was available for sequencing. b) Chromatograms showing the NBN and ATR variants in sample 2 against control DNA. Whole exome sequencing was performed on the circled samples, where shading indicates an affected individual. 
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